This paper documents that the physical appearance of CEOs, specifically excess body weight, is priced in the capital market. In the absence of explicit health disclosures,market participants interpret obesity as a proxy for latent health risks and potential managerial disrupts, thereby demanding a compensation premium. Our analysis reveals that (1) IPOs of firms with obese CEOs have lower first-day performance, (2) these firms achieve a lower valuation, (3) the stocks of these firms have lower liquidity and (4) they provide higher stock returns thereafter. A quasi-natural experiment based on the invention of anti-obesity medications provides supporting causal evidence.